Description
Quizartinib is an anticancer chemotherapeutic compound that inhibits FMS-like tyrosine kinase 3 (FLT3), c-Kit, and PDGFR. Quizartinib is clinically used to treat acute myelogenous leukemia. In cellular models, quizartinib induces apoptosis and inhibits proliferation. This compound also inhibits ATP-binding cassette ABCG2, also known as breast cancer resistance protein. Quizartinib is supplied as a crystalline solid. Quizartinib is soluble in DMSO to 33 mg/mL, in water to <0.3 mg/ml, and in ethanol to <0.5 mg/ml. If Quizartinib needs to be stored long term, we recommend storing the solid Quizartinib and not storing the Quizartinib in solution due to potential loss of stability.
References
Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013 Sep 26. [Epub ahead of print]. PMID: 24070241.
Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One. 2013;8(8):e71266. PMID: 23967177.
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013 Mar 7;12:19. PMID: 23497317.
Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009 Oct 1;114(14):2984-92. PMID: 19654408.
